| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2025 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.015 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Active | N/A |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Eye and nose irritation; stomach discomfort |
| Arsenic | Health-Based | N/A | 0.015 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.015 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Jul 15, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jul 15, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jul 15, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jul 15, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Public Notice | Monitoring | N/A | N/A | Jul 6, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jul 1, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jul 1, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.014 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.015 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Aug 16, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 16, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 28, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 28, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2021 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 9, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 9, 2021 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 14, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 14, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 14, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 14, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 10, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 10, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 10, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 10, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 24, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 24, 2021 | Resolved | N/A |